logo.jpg
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 ...
logo.jpg
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...
Logo 1.png
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
March 15, 2021 08:05 ET | Aeterna Zentaris Inc
- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of intellectual property for the development of a...
Logo 1.png
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
November 16, 2020 08:05 ET | Aeterna Zentaris Inc
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...
Logo 1.png
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
July 07, 2020 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...